Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Cabilly patents: status quo and relevance for antibody companies.

Literature DB >> 22453097

The Cabilly patents: status quo and relevance for antibody companies.

Abstract

This article discusses the status quo of the Cabilly patents, their scope of protection and the role these patents play for the therapeutic antibody industry in Europe and the US.

Mesh：

Substances：
Antibodies

Year: 2012 PMID： 22453097 PMCID： PMC3361663 DOI： 10.4161/mabs.4.2.19253

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

2 in total

Review 1. Engineered protein scaffolds as next-generation antibody therapeutics.

Authors: Michaela Gebauer; Arne Skerra
Journal: Curr Opin Chem Biol Date: 2009-06-06 Impact factor: 8.822

2. Intellectual property protection: strategies for antibody inventions.

Authors: Ulrich Storz
Journal: MAbs Date: 2011-05-01 Impact factor: 5.857

2 in total

1. Gene patent practice across plant and human genomes.

Authors: Osmat A Jefferson; Deniz Köllhofer; Thomas H Ehrich; Richard A Jefferson
Journal: Nat Biotechnol Date: 2015-10 Impact factor: 54.908

Review 2. Rituximab: how approval history is reflected by a corresponding patent filing strategy.

Authors: Ulrich Storz
Journal: MAbs Date: 2014-05-19 Impact factor: 5.857

2 in total